STOCK TITAN

Milestone Pharmaceuticals Inc. - $MIST STOCK NEWS

Welcome to our dedicated page for Milestone Pharmaceuticals news (Ticker: $MIST), a resource for investors and traders seeking the latest updates and insights on Milestone Pharmaceuticals stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Milestone Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Milestone Pharmaceuticals's position in the market.

Rhea-AI Summary
Milestone Pharmaceuticals Inc. (MIST) reports financial results, plans to resubmit NDA for etripamil in PSVT early 2Q 2024, extends cash runway to 2026, and receives FDA guidance for AFib-RVR. Positive results from ReVeRA Phase 2 study of etripamil in AFib-RVR presented at AHA Scientific Sessions 2023. Financially, Milestone had $66.0 million in cash as of December 31, 2023, with no revenue in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4%
Tags
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (MIST) will participate in a panel discussion at the TD Cowen 44th Annual Health Care Conference on March 5, 2024. The webcast will be available live and on replay for 90 days on Milestone's website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.17%
Tags
conferences
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. announces the pricing of its underwritten public offering, expecting to raise around $30.0 million through the sale of common shares and pre-funded warrants.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.13%
Tags
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (MIST) announces the commencement of an underwritten public offering of common shares and pre-funded warrants to certain investors. The company aims to use the net proceeds for the development of etripamil in cardiovascular indications and general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.13%
Tags
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) plans to resubmit the NDA for etripamil to the FDA for PSVT treatment following a Refusal to File letter. The company will restructure data sets and reformat files based on FDA guidance. No additional clinical trials are required. Cash conservation measures will fund operations until mid-2025, with potential $75 million payment upon FDA approval.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
24.12%
Tags
none
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) for the New Drug Application (NDA) for self-administered etripamil nasal spray for the treatment of paroxysmal supraventricular tachycardia (PSVT).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-30.9%
Tags
none
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (MIST) to Participate in Fireside Chat at Piper Sandler 35th Annual Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.16%
Tags
conferences
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) submits New Drug Application for CARDAMYST™ nasal spray to treat PSVT and reports positive Phase 2 data for etripamil in AFib-RVR. The company plans to host an Investor and Analyst Webcast to review the ReVeRA Phase 2 study results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-19.59%
Tags
-
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) announced positive Phase 2 data for etripamil nasal spray, showing a statistically significant reduction in ventricular rate by 30 beats per minute for episodes of atrial fibrillation with rapid ventricular rate compared to placebo. The results support further clinical development in a Phase 3 trial for the management of AFib-RVR. Safety and tolerability data were generally consistent with previous studies, indicating potential for self-administered etripamil for AFib-RVR treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Milestone Pharmaceuticals Inc. (Nasdaq: MIST) will host a virtual investor and analyst webcast on November 13, 2023, focusing on the results from the ReVeRA Phase 2 study of investigational new drug etripamil in patients with atrial fibrillation with rapid ventricular rate. Key opinion leaders, including A. John Camm, MD, and Sean Pokorney, MD, will join the webcast.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.39%
Tags
conferences clinical trial
Milestone Pharmaceuticals Inc.

Nasdaq:MIST

MIST Rankings

MIST Stock Data

79.89M
33.92M
0.63%
33.66%
1.05%
Medicinal and Botanical Manufacturing
Manufacturing
Link
United States of America
MONTREAL

About MIST

milestone pharmaceuticals is a biotechnology company located in 6100 royalmount ave, montreal, qc, canada.